Kyverna Therapeutics KYTX 深 沪
已收盘 12-24 16:00:00 美东时间
8.99
+0.110
+1.24%
华盛通- 最 高9.23
- 今 开8.86
- 成交量 86.00万股
- 最 低 8.7636
- 昨 收 8.88
- 总市值 3.89亿
- 52周最高 13.67
- 市盈率 静 --
- 换手率 1.99%
- 52周最低 1.78
- 委 比 61.09%
- 总股本 4324.57万
- 历史最高 35.06
- 量 比 0.15
- 振 幅 5.25%
- 历史最低 1.78
- 每 手 1
- 风险率 1.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
12-18 01:06
Kyverna Therapeutics Announces ~$100M Public Offering Of ~13.334M Shares At A Price Of $7.50/Share
- Kyverna Therapeutics, Inc. (NASDAQ:KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an
12-17 22:27
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
Biggest stock movers Tuesday: RILY, ORGO, KYTX, RC, LWLG and more
U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's biggest stock...
12-16 18:17
美股牛股 | KYTX大涨超23%，Miv-cel临床试验取得积极成果；以星航运涨近9%，获瑞士航运集团收购要约
KYTX大涨超23%，Miv-cel临床试验取得积极成果；IMNM涨近16%，实验性药物晚期临床试验达主要终点；以星航运涨近9%，获瑞士航运集团收购要约>>
12-16 19:53
Kyverna Therapeutics announces $100M proposed public offering
Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday that it has commenced an underwritten public offering of $100M of shares, and underwriters will be granted a 30-day option to purchase up to an a...
12-16 05:40
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With
12-15 20:26
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
Kyverna Therapeutics will host a live webcast and conference call on December 15, 2025, at 8:00 am ET to discuss topline results from its Phase 2 KYSA-8 clinical trial evaluating KYV-101 for stiff person syndrome (SPS). KYV-101 is an investigational autologous CD19 CAR T-cell therapy targeting B-cell-driven autoimmune diseases. Registration links for the call and webcast details are provided, along with information about Kyverna's broader pipelin...
12-14 19:30
美股机会日报 | 美联储最青睐通胀指标来袭！9月PCE数据将公布；高盛发声：本月降息25个基点已成定局！
美联储最青睐通胀指标来袭！9月PCE数据将公布；高盛发声：美联储本月降息25个基点已成定局；美股三大指数期货盘前上涨，百度盘前大涨约5%>>
12-05 21:06
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
